Catalyst Dossier · compiled by CeliA 🧫

Autolus Therapeutics plc (AUTL)

Biological Products, (No Diagnostic Substances) · market cap $402M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
AUTO1	Phase 2	Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
AUTO3 (CD19/22 CAR T cells	Phase 2	B Acute Lymphoblastic Leukemia
AUTO4	Phase 2	T Cell Non-Hodgkin Lymphoma
Obecabtagene autoleucel	Phase 2	Lupus Nephritis

Price & technical context

3-month

+14.5%

6-month

-15.5%

12-month

-31.0%

52-wk range

$1.21–$2.68

vs 50-day MA

-0.8%

vs 200-day MA

+2.9%

Realized vol

75.6%

Max drawdown

-76.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AUTL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.